Skip to main content
SpringerLink
Log in

Antisense-Mediated Exon Skipping to Shift Alternative Splicing to Treat Cancer

  • Protocol
  • First Online:
Exon Skipping

Part of the book series: Methods in Molecular Biology ((MIMB,volume 867))

Abstract

Manipulation of alternative splicing is a unique way of regulating gene expression. Here, a detailed protocol is presented for modification of HER2 pre-mRNA alternative splicing. A 20-mer splice switching oligonucleotide (SSO) targeting exon 15 in HER2 pre-mRNA induced skipping of exon 15, resulted in significant downregulation of full-length HER2 mRNA and protein expression in HER2-overexpressing breast cancer cell line SK-BR-3.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Keren H, Lev-Maor G, Ast G (2010) Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet 11:345–355

    Article  PubMed  CAS  Google Scholar 

  2. Blencowe B (2006) Alternative splicing: new insights from global analyses. Cell 126:37–47

    Article  PubMed  CAS  Google Scholar 

  3. Kim E, Goren A, Ast G (2007) Insights into the connection between cancer and alternative splicing. Trends Genet 24:7–10

    Article  PubMed  Google Scholar 

  4. Wood M, Yin H, McClorey G (2007) Modulating the expression of disease genes with RNA-based therapy. PLoS Genet 3:e109

    Article  PubMed  Google Scholar 

  5. Sazani P, Graziewicz M, Kole R (2008) Splice switching oligonucleotides as potential therapeutics. In: Crooke S (ed) Antisense drug technology, 2nd edn. CRC Press LLC, Boca Raton, pp 89–114

    Google Scholar 

  6. van Ommen G, van Deutekom J, Aartsma-Rus A (2008) The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther 10:140–149

    PubMed  Google Scholar 

  7. Aartsma-Rus A, van Ommen G (2007) Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13:1609–1624

    Article  PubMed  CAS  Google Scholar 

  8. Mercatante D, Mohler J, Kole R (2002) Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 277:49374–49382

    Article  PubMed  CAS  Google Scholar 

  9. Mercatante D, Bortner C, Cidlowski J, Kole R (2001) Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. J Biol Chem 276:16411–16417

    Article  PubMed  CAS  Google Scholar 

  10. Bruno I, Jin W, Cote G (2004) Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum Mol Genet 13:2409–2420

    Article  PubMed  CAS  Google Scholar 

  11. Shiraishi T, Eysturskarð J, Nielsen P (2010) Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions. BMC Cancer 10:342

    Article  PubMed  CAS  Google Scholar 

  12. Shieh J-J, Liu K-T, Huang S-W, Chen Y-J, Hsieh T-Y (2009) Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. J Invest Dematol 129:2497–2506

    Article  CAS  Google Scholar 

  13. Renshaw J, Orr R, Walton M, Te-Poele R, Williams R, Wancewicz E, Monia B, Workman P, Pritchard-Jones K (2004) Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival. Mol Cancer Ther 3:1467–1483

    PubMed  CAS  Google Scholar 

  14. Pankratova S, Nielsen B, Shiraishi T, Nielsen P (2010) PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: specific skipping of erbB-2 exon 19 coding for the ATP catalytic domain. Int J Oncol 36:29–38

    PubMed  CAS  Google Scholar 

  15. Brambilla C, Folini M, Gandellini P, Daprai L, Daidone M, Zaffaroni N (2004) Oligomer-mediated modulation of hTERT alternative splicing induces telomerase inhibition and cell growth decline in human prostate cancer cells. Cell Mol Life Sci 61:1764–1774

    Article  PubMed  CAS  Google Scholar 

  16. Wan J, Sazani P, Kole R (2009) Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. Int J Cancer 124:772–777

    Article  PubMed  CAS  Google Scholar 

  17. Hynes N, Stern D (1994) The biology of erbB-2/neu-HER-2 and its role in cancer. Biochim Biophys Acta 1198:165–184

    PubMed  Google Scholar 

  18. Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61:1–13

    Article  PubMed  CAS  Google Scholar 

  19. Moasser M (2006) Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26:6577–6592

    Article  Google Scholar 

  20. Sierakowska H, Sambade M, Agrawal S, Kole R (1996) Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA 93:12840–12844

    Article  PubMed  CAS  Google Scholar 

  21. Altschul S, Gish W, Miller W, Myers E, Lipman D (1990) Basic local alignment search tool. J Mol Biol 215:403–410

    PubMed  CAS  Google Scholar 

  22. Cartegni L, Wang J, Zhu Z, Zhang M, Krainer A (2003) ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31:3568–3571

    Article  PubMed  CAS  Google Scholar 

  23. Levin A, Yu R, Geary R (2008) Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Crooke S (ed) Antisense drug technology. CRC Press LLC, Boca Raton, pp 183–215

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of North Carolina, Chapel Hill, NC, USA

    Jing Wan

Authors
  1. Jing Wan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jing Wan .

Editor information

Editors and Affiliations

  1. Dept. Human & Clinical Genetics, Leiden University Medical Center, Einthovenweg 20, Leiden, 2333 ZC, Netherlands

    Annemieke Aartsma-Rus

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Wan, J. (2012). Antisense-Mediated Exon Skipping to Shift Alternative Splicing to Treat Cancer. In: Aartsma-Rus, A. (eds) Exon Skipping. Methods in Molecular Biology, vol 867. Humana Press. https://doi.org/10.1007/978-1-61779-767-5_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-767-5_13

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-61779-766-8

  • Online ISBN: 978-1-61779-767-5

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation